Every earnings call for SMSPHARMA — management tone, guidance, KPIs and promise tracking, quarter by quarter.
SMSPHARMA · 3 transcripts · Healthcare · latest Q4 FY26SMS Pharmaceuticals Limited has 3 earnings calls on record here, a Healthcare company, most recently Q4 FY26. Each quarter is scored on revenue, margins, guidance delivery and the questions management left unanswered — so the gap between what was promised and what was delivered is easy to read.
Revenue ₹238 cr; EBITDA (Q4 FY26) ₹40 cr; EBITDA Margin (Q4 FY26) 17%. FY26 Revenue grew 13% to ₹887 crores.
Read full transcript & analysisRevenue (Q2 FY26) ₹242 cr (+23% YoY); EBITDA (Q2 FY26) ₹48 cr (+54% YoY); EBITDA Margin (Q2 FY26) 20.0%. PAT grew 80% YoY to INR25.3 crores, highest ever in a single quarter.
Read full transcript & analysisRevenue ₹248 cr (+43% YoY); EBITDA ₹41 cr (+21% YoY); EBITDA Margin 16%. FY25 PAT grew 39% YoY to INR69 crores.
Read full transcript & analysis